An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity

Statins are an important class of medications in reducing the risk of cardiovascular events as well as overall mortality. However, a well-known adverse effect of statins is skeletal muscle toxicity, which may lead to abrupt discontinuation of the statin. In turn, patients may miss out on the benefit...

Descripción completa

Detalles Bibliográficos
Autor principal: Alzghari, Saeed K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029739/
https://www.ncbi.nlm.nih.gov/pubmed/29974012
http://dx.doi.org/10.7759/cureus.2557
_version_ 1783337013416558592
author Alzghari, Saeed K
author_facet Alzghari, Saeed K
author_sort Alzghari, Saeed K
collection PubMed
description Statins are an important class of medications in reducing the risk of cardiovascular events as well as overall mortality. However, a well-known adverse effect of statins is skeletal muscle toxicity, which may lead to abrupt discontinuation of the statin. In turn, patients may miss out on the benefits of statin therapy. An important factor to consider is a patient's solute carrier organic anion transporter 1B1 (SLCO1B1) gene T521C polymorphism status. Herein, an overview of the pharmacogenetics of SLCO1B1 is provided as well as recommendations for use in practice.
format Online
Article
Text
id pubmed-6029739
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-60297392018-07-04 An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity Alzghari, Saeed K Cureus Cardiology Statins are an important class of medications in reducing the risk of cardiovascular events as well as overall mortality. However, a well-known adverse effect of statins is skeletal muscle toxicity, which may lead to abrupt discontinuation of the statin. In turn, patients may miss out on the benefits of statin therapy. An important factor to consider is a patient's solute carrier organic anion transporter 1B1 (SLCO1B1) gene T521C polymorphism status. Herein, an overview of the pharmacogenetics of SLCO1B1 is provided as well as recommendations for use in practice. Cureus 2018-04-30 /pmc/articles/PMC6029739/ /pubmed/29974012 http://dx.doi.org/10.7759/cureus.2557 Text en Copyright © 2018, Alzghari et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Alzghari, Saeed K
An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity
title An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity
title_full An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity
title_fullStr An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity
title_full_unstemmed An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity
title_short An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity
title_sort unnecessary pain: using pharmacogenetics for statin-related skeletal muscle toxicity
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029739/
https://www.ncbi.nlm.nih.gov/pubmed/29974012
http://dx.doi.org/10.7759/cureus.2557
work_keys_str_mv AT alzgharisaeedk anunnecessarypainusingpharmacogeneticsforstatinrelatedskeletalmuscletoxicity
AT alzgharisaeedk unnecessarypainusingpharmacogeneticsforstatinrelatedskeletalmuscletoxicity

Ejemplares similares